Nov 3, 5:27 PM ET
Ashland reported preliminary fourth-quarter fiscal 2026 sales of $498 million, up 4% from the prior-year quarter, and adjusted EBITDA of $121 million, up 2%. GAAP results were weaker: a net loss of $16 million compared with net income of $32 million a year earlier. The company also issued fiscal 2027 guidance of $1,905 million to $1,975 million in sales and $405 million to $435 million in adjusted EBITDA.
- Q4 sales were $498 million, up 4%; sales volumes rose 3% and pricing rose 2%.
- Net loss was $16 million, or ($0.35) per diluted share; adjusted diluted EPS was $1.12 versus $1.08 a year earlier.
- Specialty Additives adjusted EBITDA fell 31% to $20 million, while Life Sciences adjusted EBITDA rose 16% to $64 million.
- Fiscal 2027 guidance: sales of $1,905 million to $1,975 million and adjusted EBITDA of $405 million to $435 million; fiscal 2026 adjusted EBITDA was $385 million.
Read the filing on SEC.gov ↗
Sep 25, 4:30 PM ET
Ashland amended and restated its existing European accounts receivable securitization program, with a facility limit of €125 million, extending the scheduled termination date to September 21, 2029. Bank of America, N.A. continues as administrative and structuring agent, and its committed purchaser role moved to Bank of America Europe DAC. The filing describes the changes as routine market-standard updates, and it discloses no change to the facility limit.
- Agreement dated September 24, 2026 amends the EU A/R Facility originally set up under documents dated October 19, 2023
- Scheduled termination date extended to September 21, 2029
- Aggregate facility limit of €125 million is unchanged in the filing
- Bank of America Europe DAC replaces Bank of America, N.A. as committed purchaser
Read the filing on SEC.gov ↗
Jul 31, 4:30 PM ET
Ashland Inc. entered into a Fifth Amendment to its Receivables Purchase Agreement with PNC Bank on July 30, 2026. The amendment keeps commitments of up to $70 million and extends the facility's termination date from September 11, 2026 to July 28, 2028. The filing describes this as a routine update to a financing arrangement, with no change to the commitment amount.
- Commitments under the accounts receivable securitization facility remain up to $70 million.
- The RPA termination date moves from September 11, 2026 to July 28, 2028.
- The amendment is dated July 30, 2026, and PNC Bank, National Association is administrative agent.
- The filing says the amendment makes other updates consistent with current market standards, without giving details.
Read the filing on SEC.gov ↗
Jul 28, 5:12 PM ET
Ashland Inc. appointed Peter Thomas and Allen Spizzo as independent directors on July 27, 2026, and entered into a Cooperation Agreement with stockholder Ancora Holdings Group, LLC. The company also formed a Capital Allocation Advisory Committee to make recommendations to the Board on capital allocation strategy. The filing does not include financial results, so it gives shareholders governance changes rather than a measure of operating performance.
- Peter Thomas and Allen Spizzo appointed as independent directors effective July 27, 2026; Board temporarily expands to 11 members, then reduces to 10 at the 2027 Annual Meeting
- Cooperation Agreement with Ancora includes voting commitments and standstill obligations, and remains in effect through a Standstill Period tied to the 2028 Annual Meeting notice deadline
- Capital Allocation Advisory Committee chaired by Scott A. Tozier, with Thomas as Vice Chair and Guillermo Novo as non-voting member
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
